Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase 1 15Phase 3 11Phase 1/2 5Phase 2/3 3Phase EARLY_PHASE1 2

Status

Terminated 8Active not recruiting 6Completed 5Recruiting 4Withdrawn 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Oligodendroglioma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Immunoglobulin G × Clear all
NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02581787 2024-03-27

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

Stanford University

Phase 1/2 Completed
28 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03309878 2023-09-21

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
8 enrolled 10 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02499835 2023-08-01

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
66 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
116 enrolled 17 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡